

Adherium exceeds CY2025 device shipment milestones

Key highlights:

- Adherium overachieves its goal of 4,000 devices shipped to patients across all channels before calendar year end
- Of the total target, more than 2,000 Hailie® devices shipped to Remote Patient Monitoring (RPM)
 patients, surpassing the Company's target for CY2025
- This shipment milestone represents the most operationally significant growth objective for
 Adherium in CY2025 with strong, repeatable device uptake forecast for the New Year and beyond.

Melbourne, Australia – 24 December 2025: Adherium Limited (ASX:ADR), a global leader in digital respiratory management and developer of the US FDA-cleared Hailie® Smartinhaler® platform is pleased to announce that it has exceeded two key commercial milestones for calendar year 2025, with shipments now surpassing both its 2,000 Remote Patient Monitoring (RPM) patient target and 4,000 total patient shipment goal for CY2025.

The Company's most recent quarter-to-date sales update (ASX: 15 December 2025) outlined clear shipment growth trajectory for the Hailie® Smartinhaler® platform. Adherium can now confirm that actual shipment volumes have exceeded 4,600 devices moving ahead of the curve illustrated in those updates, reflecting strong conversion and onboarding across its RPM and non-RPM channels.

Specifically:

- RPM patient shipments have now exceeded 2,034, surpassing the Company's publicly stated CY2025 objective and continuing to grow through year-end.
- Total devices across all channels have exceeded 4,666, representing a meaningful acceleration from earlier periods.


The 4,000 total shipment goal, inclusive of the 2,000 RPM target, represented the most operationally demanding growth objective for CY2025. Exceeding this milestone with RPM deliveries continuing through the holiday period, reinforces management's confidence in achieving near-term milestones, sustaining growth momentum, and executing against its broader patient growth ambitions, including the 10,000 active RPM patient target, set for the end of CY2026.

Following the recent establishment of key partnerships and ongoing clinic activations, the RPM channel has emerged as a key driver of near-term growth, providing Adherium with direct ownership of patient relationships, recurring revenue visibility, and a scalable platform to demonstrate delivery capability to future value based care providers.





Importantly, device shipments continue to act as a lead indicator to revenue growth, with monthly insurance reimbursed and billable revenue recognised as patients are activated.



The RPM channel enables Adherium to test, refine and scale critical operational infrastructure across an expanding patient cohort - a capability that is central to demonstrating readiness to support significant agreements with Value-Based Care US insurance providers and larger patient populations, fueling future business channels.



Adherium CEO Dawn Bitz commented: "Surpassing both our 2,000 RPM shipment goal and our 4,000 total patient milestone, then exceeding 4,600 devices, is a significant validation of our strategy and execution. Importantly, with further RPM shipments continuing over the coming days, even through the shorter holiday period, this performance now places us ahead of the shipment trajectory we previously communicated to the market.

"I would like to thank our team for working hard to achieve these targets, and also to sincerely thank our shareholders for their continued support throughout 2025. Your confidence has enabled the Company to invest in systems, people and partnerships that are now delivering measurable commercial results."

Outlook

Adherium remains focused on achieving its CY2025 patient shipment and revenue objectives, while continuing to scale its RPM platform as a foundation for broader channel expansion. With strong leading indicators evident via the number of RPM devices shipped, the Company believes it is well positioned to deliver continued growth into CY2026. This update does not constitute a change to previously issued guidance.

Learn more at adherium.com

This announcement contains forward-looking statements which are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ from those expressed or implied. Companies such as Adherium are subject to a range of risks and uncertainties, including, but not limited to reimbursement timing, customer or site activation rates, and operational capacity. Investors are cautioned not to place undue reliance on forward-looking statements and should conduct their own independent assessment of these risks and, where appropriate, seek advice from a licensed financial adviser prior to making any investment decision.

This ASX announcement was approved and authorised for release by the Board of Adherium.

- ENDS -

Investor Enquiries
Adherium Limited
investors@adherium.com

Media Enquiries:

Haley Chartres H^CK Director haley@hck.digital

About Adherium (ASX: ADR):

Adherium is a provider of integrated digital health solutions and a worldwide leader in connected



respiratory medical devices, with more than 180,000 sold globally. Adherium's Hailie® platform solution provides clinicians, healthcare providers and patients access to remotely monitor medication usage parameters and adherence, supporting reimbursement for qualifying patient management. The Hailie® solution includes a suite of integration tools to enable the capture and sharing of health data via mobile and desktop apps, Software Development Kit (SDK) and Application Programming Interface (API) integration tools, and Adherium's own broad range of sensors connected to respiratory medications. Adherium's Hailie® solution is designed to provide visibility to healthcare providers of medication use history to better understand patterns in patient respiratory disease. Learn more at <u>adherium.com</u>